1st Quarter - Report — WILLIAMS AND JENSEN, PLLC for MERCK & CO INC (2020)

Firm

WILLIAMS AND JENSEN, PLLC

Client

MERCK & CO INC

Income

$80,000

Expenses

—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to corporate tax including international tax proposals: Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).

Lobbyist	Covered position, as disclosed
CHRISTOPHER W HATCHER	—
SUSAN HIRSCHMANN	COS, Rep Van Hilleary and Majority Whip
CHERYL LYNN JAEGER	—
KARINA LYNCH	—

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Animals ANI

Monitor issues as they relate to animal health . Issues concerning the Animal Drug User Fee Act.

Lobbyist	Covered position, as disclosed
SCOTT GRAVES	Deputy Chief of Staff, Rep Conaway; COS, Rep Farenthold, COS, Rep Conaway; Staff Director, House Ag Committee
CHERYL LYNN JAEGER	Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Plicy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox
KARINA LYNCH	Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs.
MATTHEW S VALESKO	—

Contacted: Food & Drug Administration (FDA); SENATE; White House Office; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

International trade issues and agreements; Monitor pending trade issues.

Lobbyist	Covered position, as disclosed
CHRISTOPHER W HATCHER	—
CHERYL LYNN JAEGER	Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
KARINA LYNCH	—

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE; Food & Drug Administration (FDA)

Policies impacting Medicare Part D. Drug Development and Public Health Preparedness. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Lobbyist	Covered position, as disclosed
SUSAN HIRSCHMANN	COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA	—
CHERYL LYNN JAEGER	Shrd employee, Ofc of the Speaker & Ofc of VA 7;Sr policy adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
KARINA LYNCH	Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Government Affairs

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; SENATE

Bills named: H.R. 604 (116th), H.R. 748 (116th)

Health Issues HCR

Drug safety; Congressional oversight issues; Issues related to vaccines and drug pricing; Drug pricing under 340B program; General education about FDA approval policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Lobbyist	Covered position, as disclosed
SUSAN HIRSCHMANN	—
CHERYL LYNN JAEGER	—
KARINA LYNCH	—

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 604 (116th), H.R. 3 (116th), H.R. 748 (116th), S. 2543 (116th)

Medicare/Medicaid MMM

Payment policies for Part B prescription drugs; Rebates and co-pays for Medicare Part D drug benefits; Possible revisions in structure and operation of Medicare and Medicaid drug policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

Lobbyist	Covered position, as disclosed
SUSAN HIRSCHMANN	—
MATTHEW B HOEKSTRA	—
CHERYL LYNN JAEGER	Shared employee, Ofc of the Speaker and Ofc of VA 7th; Sr Policy Advisor, Majority Leader, Rep. Eric Cantor; Sr. Advisor, Majority Whip, Rep Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep. Christopher Cox
KARINA LYNCH	—

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 748 (116th), H.R. 604 (116th), S. 2543 (116th), H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.